<ѻýҕl>Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancerѻýҕl> No improvement in PFS versus standard for older patients ineligible for intensive therapy Dec 21, 2021
<ѻýҕl>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻýҕl> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻýҕl>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻýҕl> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻýҕl>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphomaѻýҕl> Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<ѻýҕl>Virgil Abloh's Cardiac Angiosarcomaѻýҕl> The fashion designer's death due to this rare form of cancer took the world by surprise Dec 15, 2021
<ѻýҕl>Gene Therapy Resolves Severe Pain Events in Sickle Cell Diseaseѻýҕl> LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<ѻýҕl>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻýҕl> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻýҕl>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCLѻýҕl> Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<ѻýҕl>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/Bѻýҕl> Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<ѻýҕl>In the Story of Our Practice, We're Always the Heroѻýҕl> When is it right to challenge our medical colleagues? Dec 14, 2021
<ѻýҕl>R-CHOP Toppled in First-Line DLBCL Trialѻýҕl> Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<ѻýҕl>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻýҕl> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻýҕl>β-Thalassemia Patients Go Transfusion-Free With Gene Therapyѻýҕl> Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<ѻýҕl>R2 Maintenance for Elderly MCL Patients Worth the Risk?ѻýҕl> Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<ѻýҕl>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻýҕl> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻýҕl>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancerѻýҕl> No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
<ѻýҕl>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancerѻýҕl> Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<ѻýҕl>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphomaѻýҕl> Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<ѻýҕl>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myelomaѻýҕl> Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<ѻýҕl>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphomaѻýҕl> Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<ѻýҕl>Upfront IDH1 Inhibitor Triples Survival in Older AMLѻýҕl> Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<ѻýҕl>Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Productѻýҕl> FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
<ѻýҕl>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancerѻýҕl> Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<ѻýҕl>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancerѻýҕl> Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<ѻýҕl>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancerѻýҕl> Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<ѻýҕl>Ethics Consult: Should Doctor Inform Patient's Family of Diagnosis? MD/JD Weighs Inѻýҕl> You voted, now see the results and an expert's discussion Dec 10, 2021
<ѻýҕl>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancerѻýҕl> Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<ѻýҕl>Highly Mutated Breast Cancer Responds to Immunotherapyѻýҕl> Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<ѻýҕl>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Siteѻýҕl> Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<ѻýҕl>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Statusѻýҕl> However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<ѻýҕl>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancerѻýҕl> Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<ѻýҕl>Black Women Most at Risk for Post-Surgical Lymphedemaѻýҕl> Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<ѻýҕl>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancerѻýҕl> Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<ѻýҕl>BRAF Inhibition in Pediatric Ameloblastoma of the Jawѻýҕl> Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state Dec 07, 2021
<ѻýҕl>Hemostatic Powder on Par for Stopping Acute Upper GI Bleedsѻýҕl> In non-inferiority trial, TC-325 matched standard therapy for nonvariceal lesions Dec 07, 2021
<ѻýҕl>Genomic Profiling Improves Outcomes in Breast Cancerѻýҕl> PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<ѻýҕl>But the Cancer Was 'Indolent'ѻýҕl> Tread carefully when offering patients an optimistic outlook Dec 07, 2021
<ѻýҕl>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancerѻýҕl> Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<ѻýҕl>Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastomaѻýҕl> "I've never seen anything like this," researcher says of 3-year event-free survival rate Dec 06, 2021
<ѻýҕl>Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancerѻýҕl> Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021